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Graft-versus-host disease (GVHD) is still a major complication of allogeneic stem cell transplantation (allo-SCT).
The pathophysiology of GVHD is a multistep process initiated by tissue damage and proinﬂammatory cytokine
cascades induced by the pretransplantation conditioning therapy. This eventually results in Th1-driven tissue
damage. However, increasing evidence indicates the involvement of IL17-producing T cells in GVHD pathogen-
esis. Both CD4þ and CD8þ IL17-producing T cells are suspected of initiating the Th1 response and aggravating
tissue inﬂammation, resulting in full-blown GVHD. In this review, we discuss the involvement of IL17-producing
Tcells in GVHDand the factors involved in their expansion, differentiation, and activation. Different dendritic cell
(DC) subsets, such as plasmacytoid DCs and DC NK lectin group receptor 1þmyeloid DCs have the capability to
stimulate Th/Tc17 responses through the release of cytokines. Pivotal cytokines include IL1b, IL6, IL23, and TGFb,
which are known to drive differentiation and expansion of IL17-producing Tcells, and these cytokines are highly
elevated in patients after allo-SCT. Potent activators of these DC subsets are motifs that are released upon tissue
damage andmicrobial exposure during allo-SCT. These motifs aggravate the Th/Tc17 response via the activation
of various pathogen recognition receptors, thereby initiating and perpetuating GVHD. A more comprehensive
understanding of the factors and DC subsets driving the IL17 pathwaywill result in developing and testing novel
therapeutic approaches for the prevention of GVHD.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION studies indicate that other Tcell subsets, such as Th/Tc17 cells,
Graft-versus-host disease (GVHD) is still a major compli-
cation and limitation of allogeneic stem cell transplantation
(allo-SCT) [1,2]. The pathophysiology of GVHD is a multistep
process involving tissue damage and proinﬂammatory cyto-
kine cascades induced by the pretransplantation conditioning
therapy [2,3]. Furthermore, innate immune activation caused
by perturbed host-microbe interactions at epithelial barriers
increases inﬂammation and antigen presentation [4]. This
results in an excessive inﬂammatory environment in which
donor-derived CD4þ and CD8þ T cells become activated by
antigen-presenting cells. In addition, Tcell trafﬁcking towards
inﬂamed GVHD-prone organs, such as skin, lung, the
gastrointestinal tract, and liver, is strongly augmented.
Further, tissue destruction in these organs occurs in the case
of presentation of ubiquitous or epithelial expressed allo-
antigens to inﬁltrating alloreactive T cells. Moreover, den-
dritic cells (DC), macrophages, and other T cell subsets are
recruited, resulting in further enhancement of GVHD. In
particular, T helper (Th) 1-type CD4þ T cells and T cytotoxic
(Tc)-1 type CD8þ T cells play an important role in the effector
phase of GVHD pathophysiology [1,2,5]. However, recentedgments on page 757.
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14.02.007are involved in the initiation and aggravation of GVHD [6e9].
In this review, we will discuss the role of these IL17-
producing T cells in GVHD development and the potential
therapeutic strategies targeting the IL17 pathway to diminish
or prevent this detrimental complication.REQUIREMENTS FOR DIFFERENTIATION OF IL17-
PRODUCING CELLS
Generally, IL17-producing T cells differentiate from naïve
T cells, though plasticity of other T cell subsets into IL17-
secreting T cells has been shown [10]. Activation of the
transcription factor retinoic acid-related orphan receptor
(ROR)gt is essential for IL17-producing CD4þ (Th17) and
CD8þ (Tc17) T cells [11] that can be achieved via various
routes, though it generally occurs via the STAT3 signaling
pathway. STAT3 is not only responsible for the activation of
RORgt, but it can also bind and function as a promoter to
other genes involved in this process, such as IL17 [12].
Various cytokines play a major role in the activation of
STAT3, RORgt, and Th/Tc17 differentiation (Figure 1). The
importance of IL1b and IL6 has been shown in several studies,
both in mouse models as well as in vitro cultures of human
T cells [13,14]. The additional role of TGFb in this process is
still unclear, mainly due to differences in mouse and human
studies. Most mouse studies showed that TGFb is essential in
Th/Tc17 differentiation. However, human Th/Tc17 cells can be
generated in vitro without the presence of TGFb [13].Transplantation.
Figure 1. Th/Tc17 cell differentiation. Cytokines produced by dendritic cells
differentiate naive T cells (Tn) towards Th/Tc17 cells. DC indicates dendritic
cell; Tn, naive T cell; Th/Tc, helper T cell/cytotoxic T cell.
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more insight in this process. Generally, in the presence of IL1b
and IL6 (and possibly TGFb), while IFNg and IL4 are absent to
induce Th1 or Th2 skewing, differentiation to IL17-producing
T cells is initiated. In addition, IL23 plays a pivotal role in the
commitment and maintenance of Th17 cells [14].
Furthermore, IL23 was shown to play a major role in the
generation of pathogenic Tc17 cells, as IL23-treated Tc17 cells
were potent inducers of autoimmune diabetes, whereas
Tc17 cells treated with TGFb and IL6 were not [15]. Finally,
the cytokine IL21 is also involved in Th17 differentiation [16].
Upon initial activation of STAT3 by IL6, both IL21 and IL23,
along with TGFb, induced IL17 expression via the activation
RORgt. Moreover, the cytokine IL21 is also involved in self-
maintenance, as this cytokine is produced by the Th/
Tc17 cells themselves.
Multiple microenvironmental factors could also inﬂuence
Th17 differentiation. For instance, the presence of retinoic
acid in the microenvironment inhibits Th17 differentiation
and induces regulatory T cell (Treg) formation [17]. On the
other hand, several labs have described a role for the aryl
hydrocarbon receptor in Th17 differentiation [18]. These
studies showed that aryl hydrocarbon receptor ligands in-
crease Th17 responses from naïve T cells and promote auto-
immunity in mouse models. The various cytokines required
for Th/Tc17 differentiation are released from diverse immune
(eg, myeloid DC [mDC] and plasmacytoid DC [pDC]) and
nonimmune antigen-presenting cells on activation of path-
ogen recognition receptors (PRRs) by motifs released upon
tissue damage and/or microbial exposure, including vari-
ous danger-associated molecular patterns (DAMPs) and
pathogen-associated molecular patterns (PAMPs), respec-
tively. Because in the human body epithelial barriers are
inhabited by multiple microbes, both Th17 and Tc17 cells are
of particular importance in the protection against extracel-
lular microbes and defense mechanisms in the epithelial
barriers of skin, gut, and lung. The release of IL17 has, indeed,
been shown to enhance barrier defense, for example, by the
production of antimicrobial peptides. Consistently, Th/
Tc17 cells have been described to play a major role in the
initiation of autoimmune disorders and other inﬂammatory
conditions that originate at epithelial barriers, such as Crohn’s
disease and psoriasis [19]. As GVHD predominantly affects the
gut, skin, and liver, Th/Tc17 cells are also suspected to be
major players in the onset of GVHD.TH/TC17 CELLS AND THEIR ROLE IN GVHD
Indicative Data from Animal Models
Several mouse studies demonstrated the involvement of
Th/Tc17 cells in the onset and persistence of GVHD [7,20,21].Carlson et al. showed development of lethal GVHD upon
injection of in vitroegenerated Th17 cells in a bone marrow
transplantation mouse model [7]. In addition, adoptive
transfer of IL17-/- T cells delayed the occurrence of GVHD
compared with wild type (WT) T cells [21]. However, the
precise role of Th/Tc17 cells in GVHD is still debated. For
instance, Yi et al. reported initiation of Th1-driven GVHD in
the absence of IL17 [22]. To the contrary, Yi et al. also
observed IL17edriven GVHD when the Th/Tc1 cytokine IFNg
was absent [23]. A joint event was described by Yu et al., who
observed lower GVHD incidence while sparing the graft-
versus-tumor (GVT) effect, but only when both the Th/Tc17
driving transcription factor RORgt as well as Th/Tc1einduc-
ing transcription factor t-bet were targeted simultaneously
[24]. Targeting only RORgt elevated IFNg levels, whereas IL17
was highly increased when t-bet was abolished. However,
targeting both resulted in the lack of both cytokines and the
absence of GVHD.
Alternatively, the observed effect on GVHD could also be
explained by increased levels of Tregs in these mice. Inter-
estingly, Fulton et al. attenuated GVHD by only targeting
RORgt, though in this mouse model no increase in IFNg was
observed as a consequence of lacking IL17 [25]. In addition,
targeting RORgt in this mouse model only affected serum
IL17, whereas Yu et al. showed disturbed levels in several
GVHD target organs [24,25]. Taking into account the differ-
ences in human and mouse Th/Tc17 differentiation, more
insight in this process could be revealed in humanized
mouse models.
In addition to IL17, Th/Tc17 cells could also play a role in
GVHD via production of IL22 [26]. IL22, which is related to
the IL10-family, has a paradoxical role in inﬂammation with
both protective and inﬂammatory effects. Though it was
shown that IL22 produced by innate lymphoid cells pro-
tected intestinal stem cells from immune-mediated damage
during GVHD [27], IL22 is also involved in the pathogenesis
of several inﬂammatory diseases, such as rheumatoid
arthritis and psoriasis [28,29]. Interestingly, a recent study
revealed a possible role of IL22 in GVHD, as adoptive transfer
of IL22-/- instead of WT T cells reduced acute GVHD severity
[30]. However, IL17 production of IL22-/- T cells was not
affected, and an increase in Tregswas observed in thesemice,
which could also contribute to the reduced GVHD. In
conclusion, collective ﬁndings in experimental mouse
models suggests that Th/Tc17 could contribute to the path-
ophysiology of GVHD through IL17, and possibly IL22,
production.
Studies in Allo-SCT Patients
In addition to their role in mice, a key role of Th/Tc17 cells
in human GVHD pathogenesis has been reported [6,8].
Interestingly, increased levels of circulating Th17 cells have
been described in GVHD patients [8,31]. For instance, Liu
et al. showed increased circulating IL17-producing CD4þ
T cells in patients at the onset of GVHD, compared with time-
matched controls [31]. Furthermore, a single nucleotide
polymorphism (SNP) in the IL23 receptor, important in Th/
Tc17 differentiation, has shown a protective role in the
development of acute GVHD in 2 independent studies
[32,33]. However, as the functional consequence of the SNP is
yet unknown, it cannot be stated whether IL17 differentia-
tion would be inhibited or enhanced. Although the potential
involvement of Th17 cells in GVHD has been proposed by
multiple studies, Broady et al. found an expansion of Th1,
rather than of Th17 cells, in GVHD-affected skin [34].
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revert completely into Th1 cells [35]. Regarding this pro-
posed plasticity of Th17 responses, other (surface) markers
would be more reliable to study the involvement IL17-
producing T cells in GVHD. Using CD161, the distinguishing
surface marker for both CD4þ and CD8þ T cells capable of
producing IL17 [36], we recently showed decreased levels of
circulating Th/Tc17 cells in GVHD patients, although they
inﬁltrated GVHD-affected skin and gut [9]. This was in
concordance with data published by Bossard et al., who re-
ported signiﬁcantly higher absolute numbers of Th/Tc17 cells
in GVHD-affected intestinal mucosa, using the markers
CD161, RORgt, and CC chemokine receptor (CCR)6 [6]. This
suggests that Th/Tc17 cells could be involved in the onset of
GVHD via their migration potential toward GVHD target or-
gans, thereby exerting a proinﬂammatory effect, as well as
increasing the recruitment of alloreactive Th/Tc1 cells and
other immune cells. However, many factors, such as the
conditioning regimen and different post-transplantation
immune suppressive therapy, will have a prominent impact
on expansion kinetics and involvement of Th/Tc17 and Th/
Tc1 responses in GVHD in patients.
TH/TC17 TRAFFICKING TO GVHD TARGET ORGANS
Migration towards GVHD target organs could take place
via multiple chemokine axes, as Th/Tc17 cells display high
levels of the chemokine receptors CCR6 and CXCR3 [26].
Interestingly, we showed that a SNP in CCR6 present in the
donor resulted in lower GVHD incidence [37]. Its ligand,
CCL20, is constitutively expressed in the GVHD target organs,
such as the liver, colon, small intestine, lung, and skin [38].
Additionally, damage to the epidermal permeability bar-
rier, as well as stimulation with IL1bdboth known to be
elevated after conditioning of allo-SCT patientsdresults in
upregulation of CCL20 expression [9,39,40]. We, indeed,
showed that GVHD-affected skin and gut display high
expression of CCL20, both by keratinocytes and inﬁltrating
immune cells [9]. Furthermore, increased expression of the
CXCR3-ligands, CXCL9 and CXCL10, has also been described
in serum of GVHD patients and in their affected tissues [41].
These chemokines, which are strongly upregulated upon
inﬂammation, can attract migrating Th/Tc17 cells, resulting
in their recruitment into GVHD-affected tissues, and there-
fore decreased levels of circulating CXCR3þ T cells as
described in GVHD patients [41,42]. This endorses the
various migration routes of Th/Tc17 cells towards GVHD-
target tissues.
CROSSTALK OF TH/TC17 WITH TH/TC1 CELLS
Upon recruitment of Th/Tc17 cells into GVHD tissues,
other T cell subsets are attracted. Crosstalk between Th/Tc1
and Th/Tc17 cells in GVHD development is very likely, as has
also been suggested in other immune-related diseases
[43,44]. In this regard, we suggest that shortly after allo-SCT,
Th/Tc17 cells could play an important role in initiating the
GVHD response, which is thereafter overshadowed by a
tremendous Th/Tc1 response, causing the main damage in
the tissues. This hypothesis has been underscored by histo-
logical data showing that in early-stage mild gut GVHD,
higher numbers of Th17 cells were found than in patients
with severe GVHD after allo-SCT [45]. Possibly, Th/Tc17 and
Th/Tc1 responses act either sequentially or simultaneously
together in GVHD. This was also observed in inﬂammatory
bowel disease, another IL17-driven disease, in which a syn-
ergy of Th1 and Th17 cytokines was observed [43].The dependence of these subsets upon each other has
been clearly demonstrated in different studies. In the
absence of IFNg (with or without IL4), differentiation to-
wards IL17-producing T cells was increased, resulting in
augmented GVHD [23]. However, visa versa, lack of IL17
increased IFNg production, resulting in Th1-driven GVHD
[22]. Taken together, crosstalk between Th/Tc17 and Th/Tc1
cells is apparent in the setting of GVHD, in which upon
initiation of Th/T17 cells, Th/Tc1 cells will be potently acti-
vated and aggravate the disease. However, no hard evidence
yet exist for this sequential T cell response and further
research is warranted to understand dynamics and crosstalk
of these 2 cooperating T cell subsets in GVHD.FACTORS PROMOTING TH/TC17 ACTIVATION AND
EXPANSION AFTER ALLO-SCT
Role of DC Subsets
The role of DCs in GVHD development was established
more than a decade ago by Shlomchik et al. [46]. Although it
has been demonstrated that both DCs from the host as well
as from the donor can contribute, less is known about the
role of the different DC subsets in GVHD. The most common
known DCs, the mDCs, have been shown to play a role in
GVHD in several mouse models [46,47]. Especially, depletion
of host mDCs in recipient mice has been shown to prevent
GVHD. In addition, low levels of circulating mDCs in allo-SCT
patients have been described to correlate with the develop-
ment of severe acute GVHD, suggesting migration of these
cells to GVHD sites [48].
Another DC subset, which has recently been associated
with GVHD, are pDCs. Notably, increased levels of pDCs were
detected in affected gut tissue of acute GVHD patients [6].
Also, a decrease in circulating pDCs was correlated with
acute GVHD, suggesting active migration from the periphery
into inﬂamed tissue [48]. Furthermore, pDCs are capable of
producing high levels of IL1b, a key cytokine in the devel-
opment of GVHD and the IL17 differentiation pathway
[49,50]. Interestingly, it was shown that presence of IL1b
resulted in increased IL17 production by CD161-expressing
CD8þ Tc17 cells [51]. Moreover, pDC leukemia is often asso-
ciated with isolated cutaneous lesions due to skin accumu-
lation of leukemic pDCs [52], suggesting their involvement in
inﬂammatory diseases of the skin, such as GVHD.
Moreover, pDCs could be potentially activated via TLR9 by
self-DNA, released upon pretransplantation conditioning.
Although viral DNA can gain access to the intracellular TRL9
receptor, self-DNA does not gain direct entry to endosomes
and TLR9 under normal conditions. However, in the presence
of the endogenous cationic antimicrobial peptide LL37, pDCs
can be also activated by self-DNA [53]. The main function of
LL37 peptide is to prevent microbial invasion of damaged
epithelial surfaces by directly killing a broad spectrum of
pathogens, including bacteria, protozoa, fungi, and viruses.
Besides this, it has the ability to bind self-DNA, released by,
for instance, dying cells after the conditioning regimen, to
form aggregates and condensed particles that are trans-
ported into pDCs, allowing TLR9 signaling [53,54]. LL37 is
normally not expressed in healthy skin, but it is transiently
produced by keratinocytes and released by inﬁltrating neu-
trophils in response to skin wounds or infections [55]. In
psoriatic skin, LL37 has been identiﬁed as a key mediator in
pDC activation [53]. As the conditioning regimen, containing
chemotherapy and total body irradiation, probably results in
increased LL37 and self-DNA exposure, and thereby robust
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the inﬂammatory response of GVHD.
Another relevant DC subset possibly involved in the
initiation of GVHD could be DC NK lectin group receptor 1
(DNGR1)þ CD141þ mDCs. This DC subset, capable of pro-
ducing IL6, IL12, TNF, and IFN, has the capacity to induce Th17
responses [56,57]. Recently, it was shown that these DNGR1þ
DCs are activated upon interactionwith ﬁlament actin, which
has been shown to be strongly exposed upon cell damage
[58]. Because the pretransplantation conditioning regimen of
allo-SCT patients results in host tissue damage and, thereby,
possible exposure of ﬁlament actin, DNGR1þ DCs could be
activated and, thereby, promote IL17 responses.
Therefore, both pDCs as well as DNGR1þ DCs could play a
key role in the activation of IL17-producing T cells and,
thereby, the onset of GVHD.
Role of Microbe and Damage Association Patterns
The role of innate immune activation by host microbe
interactions at epithelial barriers in the pathogenesis of GVHD
is increasingly recognized [4,59,60]. In 1971, it was shown by
studies in chimeric mouse models that germ-free or gut-
decontaminated mice showed reduced GVHD-related mor-
tality [61,62]. Recently, the composition of the gut microbiota
and changes that occurred therein after allo-SCT were shown
to be pivotal in the pathogenesis of GVHD in both mice and
humans, supporting previous observations [63].
Bacteria and fungi, and also viruses, have been associated
with the occurrence of GVHD [2,64,65]. In addition, the use of
antibiotics resulted in reduced anaerobic bacteria and a lower
incidence of acute GVHD [66]. The fungus Candida albicans
has also been shown to result in increased incidence of acute
GVHD [67]. This was in line with the study of Marr et al. who
showed that prophylactic ﬂuconazole use prevented Candida
infections and resulted in a lower GVHD incidence [68].
These microbes and their PAMPs, that potentially
contribute to GVHD, are mainly present early after allo-SCT,
which is during the initiation phase of GVHD [2]. Generally,
DC activation by microbes can induce Th1, Th2, and/or Th17
responses, dependent on the type of antigen. However, most
of these commensal microbes and pathogens can elicit
strong Th17 responses. As several microbes elicit plastic
immune responses during the progress from mucosal to
systemic infection, with Th17 responses preceding Th1, it can
be imagined that Th/Tc17 might be an early event in GVHD
that precedes massive Th/Tc1edriven tissue damage. Mi-
crobes could inﬂuence Th17-mediated GVHD indirectly by
activating innate immune cells via PRRs and, more directly
and speciﬁcally, by eliciting CD4þ and CD8þ T cell responses
through the several DCs subsets. The role of the latter in
GVHD is unknown, but it is suggested by a role for microbe-
speciﬁc CD4þ Th17 and Th1 responses in colitis and synge-
neic GVHD of the gastrointestinal tract [69,70]. In addition,
Jankovic et al. showed that activation of the PRR NLRP3 by
PAMPs and DAMPs, ie, uric acid, contributed signiﬁcantly to
the occurrence of intestinal GVHD [71]. The observation that
this was mediated by IL1b, followed by a Th17 response
especially indicates the role of Th17 cell as early reactor after
activation signals.
Furthermore, it has been observed that Th17 cells respond
to several microbial antigens [72,73]. More speciﬁcally,
CD161-expressing T cells can be activated by Escherichia coli
resulting in an inﬂammatory cytokine response [72]. In
addition, IL17 secretion by CD4þ T cells was observed upon
stimulation with Candida albicans [73]. Plausibly, pDCs couldplay a role in the activation of Th17 cells bymicrobes via TLR 7
and 9 [74]. In this regard, Yu et al. found increased IL17 pro-
duction by T cells upon coculture with TLR7 stimulated pDCs
[50]. In addition, similar datawere observedwhen pDCs were
activated with Inﬂuenza A or HIV-infected cells. Also, as viral
infections by herpes simplex virus and cytomegalovirus have
been associated with the occurrence of GVHD, activation of
pDCs by these viruses could contribute to the initiation of the
disease [64,65]. Furthermore, pDCs are activated by extra-
cellular and intracellular bacterial DNA and RNA, supposedly
via TLR7 and TLR9 after CD32-mediated uptake [75,76]. In an
animal model for the Th17-driven disease multiple sclerosis,
initiated by exposure to Mycobacterium tuberculosis and
pertussis toxin, depletion of pDCs resulted in less severe
clinical symptoms as well as less Th17 cells [49]. All together,
this supports the notion that pDCs can initiate a Th/Tc17
response via activation by microbial antigens.
Role of Cytokines
Pretransplantation conditioning regimen results in tissue
damage with a subsequent rise of various (proinﬂammatory)
cytokines [77,78]. Within the ﬁrst weeks after allo-SCT, levels
of IL1b, IL6, IL8, IL10, IL21, IL23, and TNFa are increased,
which can remain high up to 12 weeks after allo-SCT [31,77].
Increased levels of IL6 have been reported in several studies
and have been correlated with the occurrence of infections
and GVHD [79,80]. Importantly, TGFb appears also elevated
during the ﬁrst weeks after allo-SCT in patients with acute
GVHD [78]. As described in previous paragraphs, these cy-
tokines are mainly produced by DCs upon activation due to
tissue damage and microbe exposure. Several of these cyto-
kines are involved in the differentiation and expansion of Th/
Tc17 cells, which could result in increased levels of Th/
Tc17 cells after allo-SCT, as previously described by us and
others [8,9].
Additionally, a trend towards higher IL17 serum levels has
been observed in patients with acute GVHD [81]. This is in
alliance with data published by Espinoza et al., who found
that patients receiving a transplant from donors with a SNP
in the promoter region of the IL17 gene were more prone to
developing GVHD [82]. Interestingly, T cells with this allele
produced more IL17 than those without. Furthermore, Lui
et al. showed increased IL17 in the serum of GVHD patients;
however, IL22, also produced by Th/Tc17 cells, was decreased
in these patients [31].
In addition to IL17 and IL22, Th/Tc17 cells also produce
IL21 to support self-renewal [16]. The lack of IL21R on T cells
prevented GVHD while sparing the GVT effect [83]. More-
over, antibody blockade of IL21 also protected mice from the
development of GVHD [84,85]. However, 2 out of these 3
models showed minimal responsive IL17 levels, and the
observed effect could also be explained by the increased
levels of Tregs [83,85]. Nevertheless, Hippen et al. showed
decreased levels of IL17 upon blockade of IL21, although also
in this study an increase of Tregs was observed [84]. In
addition, given the importance of IL21 in T cell proliferation,
blockade of IL21 also resulted in decreased numbers of
alloreactive T cells, which could also contribute to the
reduced GVHD response in this model. Taken together, the
increased levels of cytokines induced by the conditioning
regimen results in expansion and activation of Th/Tc17 cells
after allo-SCT. This could be an important, initial driver of the
development of GVHD, though the cytokines produced by
the Th/Tc17 cells might not all contribute to GVHD
development.
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Currently, GVHD treatment options rely largely on the
suppression of the whole immune system, using immuno-
suppressive drugs such as cyclosporine A and mycopheno-
late mofetil. Though these treatments can reduce GVHD
intensity in a proportion of the patients, treatment success
remains modest, especially in patients with severe GVHD
[86]. In addition, suppression of the whole immune system
predisposes patients to an increased risk of infections and
tumor relapse. Therefore, selective prevention of GVHD
would be a far more favorable strategy. With more
comprehensive understanding of which factors and T cells
subsets are involved in GVHD development, improved
targeting strategies could be exploited to prevent GVHD.
Selective GVHD prevention will likely reduce the
nonrelapse-related mortality, and, importantly, increase
quality of life.
Manipulation of T Cells in Graft and Donor Lymphocyte
Infusion
Complete or partial depletion of T cells from the graft has
the ability to reduce the occurrence of GVHD [87]. However,
crude T cell depletion strategies will also reduce the thera-
peutic GVT effect. By more speciﬁc T cell depletion strategies,
such as the depletion of only CD161þ/Th/Tc17 cells, the GVT
effect could be sustained by the non-GVHDeinitiating T cells.
Targeting the tissue homing properties, such as CCR6 or
CXCR3, on these cells is a possibility, either by depletion of
blockade of the homing capacity. However, this strategy will
be less speciﬁc for Th/Tc17 depletion. In addition, depletion
of the different DC subsets, such as pDCs and DNGR1þ DCs,
could also be a target, as speciﬁc depletion of DCs from the
graft could inhibit the initiation of GVHD. However, to spare
the GVT effect, depletion of speciﬁc DC subsets might be
more favorable.
In Vivo Manipulation of Th/Tc17 Cell Differentiation
In addition to manipulation of the graft and donor
lymphocyte infusion, in vivo targeting of Th/Tc17 cell pop-
ulations could additionally lower the generation of these
cells in time. As upregulation of RORgt is crucial in the
generation of Th/Tc17, this could be used as a target to inhibit
Th/Tc17 generation. This possibility has been shown in
different mouse models, where less GVHD was observed
upon adoptive transfer of RORgt-/- compared with WT T cells
[24,25]. However, whether this is a direct effect of lacking
Th/Tc17 cells, or whether this is due to the observed increase
of Tregs should be investigated further A possible clinical
application to apply this strategy in patients is a small
molecule inhibitor for RORgt, as described by Huh et al. [88].
However, possible side effects should be taken into account,
as studies of RORgt-/- mice have shown the role of RORgt in
processes other than Th/Tc17 development, resulting in de-
fects in lymphoid development. A putative safer option with
similar effects could be induced by isoforms of retinoic acid,
which inhibit Th17 formation and enhance Treg generation
[17]. Together, targeting RORgt could be an option to prevent
differentiation of Th/Tc17 cells, and thereby prevent the
occurrence of GVHD.
PRR Inhibitors
Prevention of GVHD could also be achieved by preventing
the activation of DCs by PAMPs and DAMPs. As these mole-
cules have been implicated in GVHD pathobiology exten-
sively, especially during the initiation phase, they could bepromising cascade targets in the prevention of GVHD [38]. By
inhibiting the PRRs, activation of pDCs and DNGR1þ mDCs
could be prevented, thereby suppressing the Th/Tc17
activation.
Cytokine Pathway Inhibition
An alternative approach to inhibit Th/Tc17 responses
would be to inﬂuence cytokine cascades involved in the IL17
pathway. Blocking IL1b, which is a major player in GVHD,
with canakinumab (IL1b antibody) or its receptor with ana-
kinra (recombinant IL1R antagonist), could interfere with the
activation of Th17 cells [89]. However, the blockade of IL1b
has shown some contradictory results in GVHD treatment
[90]. Blocking IL6 signaling could also contribute to pre-
venting GVHD [91,92]. Nevertheless, blockade of IL6 has not
resulted in clear effects on Th/Tc17 responses. A probable
mechanism by which blockade of IL6 could contribute to the
prevention of GVHD is the increased levels of Tregs observed,
with the supplementary suppression of Th/Tc1 and Th/
Tc17emediated tissue damage [92,93]. On the other hand,
promising results have been obtained by anti-IL17 (ixekizu-
mab) and anti-IL17 receptor (brodalumab) in the treatment
of the IL17-driven skin disease, psoriasis [94,95]. Although
blocking IL17 using secukinumab (IL17-blocking antibody)
was associated with increased infections in Crohn’s disease
patients, only local and no systemic fungal complications
were observed, showing the feasibility to safely interfere
with Th17 responses [96]. Promising results have also been
found by depleting the p40 subunit of IL12 and IL23 with
ustekinemab (IL12/IL23eblocking antibody), which is
approved for the treatment of psoriasis. A recent case report
showed the potency of ustekinemab in GVHD treatment, as a
complete remission was observed after treatment of steroid-
resistant GVHD with this blocking antibody [97]. However,
this also coincided with a increase in Tregs, again suggesting
that the effect is not solely Th/Tc17elineage speciﬁc. Deple-
tion of IL12 (p70) and IL23 could also be achieved using a
small molecule inhibitor, which also for psoriasis, resulted in
lower IL17 levels [98]. Moreover, molecules downstream of
the cytokine signaling, such as STAT3, could also be consid-
ered possible targets. Combined, blockades of signaling
pathways could be used for preventing and/or treating
GVHD, blocking the Th/Tc17 initiation.
CONCLUSION AND FUTURE PERSPECTIVES
In recent years, new and exciting insights have been
gained in the pathogenesis of GVHD, and increasingly, a role
for IL17-producing cells and the Th/Tc17 pathway has been
acknowledged. In the future, it might be proven that the
speciﬁc context of allo-SCT determines whether IL17-
producing T cells play an important role or not. As IL17-
producing cells are mainly involved in epithelial barrier
defenses of gut, lung, and skin, organs where GVHD occurs, it
can be anticipated that the role of the Th/Tc17 pathway in
GVHD is greatest in the presence of tissue damage (eg,
resulting from myeloablative and reduced-intensity condi-
tioning), microbial exposure (eg, infection or gut trans-
location), and the release of proinﬂammatory cytokines
including IL1b, IL6, and IL23. Consequently, IL17-producing
cells emerge and activate early on; that is, during or
directly after the conditioning-induced tissue damage and
innate immune activation. Thereafter, they set the stage for
full-blown GVHD by inducing aggravated tissue inﬂamma-
tion, immune cell recruitment, and priming alloreactive Th1/
Tc1 responses. Being an early event in GVHD, the Th/Tc17
Figure 2. Th/Tc17 pathway involved in GVHD and its potential targets. TBI indicates total body irradiation; F-actin, ﬁlament actin; DNGR1, DC NK lectin group re-
ceptor; DC, dendritic cell. DAMP, danger-associated molecular patterns; PAMP, pathogen-associated molecular patterns, Th/Tc, helper T cell/cytotoxic T cell.
A.B. van der Waart et al. / Biol Blood Marrow Transplant 20 (2014) 752e759 757pathway seems to be both a logical and suitable target for
preventive interventions, and this is most appealing as
treatment of manifested acute GVHD remains difﬁcult, with
50% being steroid refractory, and resulting in a high
mortality.
Many factors are involved in the differentiation, expan-
sion and activation of IL17-producing T cells in allo-SCT re-
cipients. Different DC subsets, such as pDCs and DNGR1þ
mDCs, have the capability to activate Th/Tc17 cells through
the release of cytokines. Pivotal cytokines include IL1b, IL6,
IL23, and TGFb, which are known to drive the differentiation
and expansion of IL17-producing T cells, and these cytokines
have been shown to be elevated in patients after allo-SCT.
Potent activators of these DC subtypes are motifs that are
released on tissue damage (and microbial exposure) during
allo-SCT. These motifs aggravate the Th/Tc17 response via
activation of various PRRs, thereby initiating and perpetu-
ating GVHD.
At all these different levels, interventions are possible
(Figure 2). Attractive approaches are preventing the occur-
rence of tissue damage by using less toxic conditioning, and
inhibiting Th/Tc17 generation by scavenging PAMPs and
DAMPs that activate DCs, modulating the PRR pathways, and/
or inhibiting key cytokines with monoclonal antibodies, eg,
IL1b with anakinra and canakinumab and IL23 with
ustekinumab.
In addition, Th/Tc17 can be targeted more speciﬁcally by
depleting them from the graft, inhibiting their tissue-homing
properties, or inhibiting their effector cytokines and related
receptors, especially IL17, with ixekizumab and brodalumab,
for example.
Although many new preventive strategies seem prom-
ising, further investigations are warranted. Still, many
question remain to be answered on the role of different
subsets of lymphocytes, including Th/Tc17, in acute GVHD.
Nevertheless, the insights we now gain rapidly on the IL17-
producing T cells open up new ways that can, and should
be, explored for the prevention and treatment of GVHD. This
way, we could enhance the outcome of allo-SCT and improve
the quality-of-life of hematology patients.ACKNOWLEDGMENTS
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